Synta Pharmaceutical launches its proprietary Small Molecule Hsp90-inhibitor Drug Conjugate platform

Synta Pharmaceuticals (SNTA) says it's launching its Hsp90-inhibitor Drug Conjugate platform, with the intention of creating a new class of anti-cancer therapies.

The objective is to create novel drug conjugates that exploit Hsp90 biology to selectively deliver potent anti-cancer payloads to cancer cells.

The drug developer expects to launch its first investigational new drug in next 18 months.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs